OncoMatch/Clinical Trials/NCT06308588
Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Is NCT06308588 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Blinatumomab and Asciminib for philadelphia chromosome-positive.
Treatment: Blinatumomab · Asciminib — To learn if the combination of blinatumomab and asciminib can help to control Ph+ ALL.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: BCR bcr-abl1 fusion
Disease stage
Required: Stage RELAPSED, REFRACTORY, PREVIOUSLY UNTREATED, MINIMALLY PRETREATED
previously untreated or minimally pretreated Ph-positive ALL ... relapsed/refractory Ph-positive ALL ... previously treated lymphoid blast phase CML
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Kidney function
Creatinine clearance ≥30 mL/min
Liver function
Total serum bilirubin ≤ 2 x ULN (unless due to Gilbert's syndrome); ALT ≤ 3 x ULN OR AST ≤ 3 x ULN
Cardiac function
Adequate cardiac function as assessed clinically by history and physical examination
Adequate liver function as defined by the following criteria (unless the increased values are judged to be leukemia disease related): Total serum bilirubin ≤ 2 x ULN, unless due to Gilbert's syndrome; ALT ≤ 3 x ULN, OR AST ≤ 3 x ULN. Adequate renal function defined as: Creatinine clearance ≥30 mL/min. Adequate cardiac function as assessed clinically by history and physical examination.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Montefiore Einstein Comprehensive Cancer Center · The Bronx, New York
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06308588 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require BCR?
Yes, BCR bcr-abl1 fusion is a required biomarker for enrollment.
What disease stage is eligible?
Stage RELAPSED or REFRACTORY or PREVIOUSLY UNTREATED or MINIMALLY PRETREATED is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify